Compare Sanofi SA (SNY) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs United States Natural Gas Fund — how do they compare? Sanofi SA trades at $40.05 (market cap $95.18B), while United States Natural Gas Fund trades at $11.11 (market cap $517.27M). The key difference: Sanofi SA is far larger — about 184× United States Natural Gas Fund's market cap, and Sanofi SA pays a 6.01% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and United States Natural Gas Fund for 22 Days on average.
| SNY | UNG | |
|---|---|---|
Market Cap | $95.18B | $517.27M |
Volume | 2,995,646 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $52.34 | $16.90 |
52-Week Low | $39.51 | $9.63 |
Typical Hold Time | 94 Days | 22 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
UNG trades at $11.06, up 0.28% with a bullish technical signal from moving averages. The fund reported $65.15M net income for 2024 despite zero revenue, with strong total assets of $790.02M and minimal debt. Recent news highlights natural gas market volatility with record production and geopolitical tensions influencing energy prices.
The outlook is mixed: technical strength and clean balance sheet support stability, but zero revenue and negative cash flow (-$251.70M) pose fundamental risks. Investors face exposure to natural gas price swings and supply-demand imbalances, requiring careful monitoring of energy market developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
